1-3 of 3
Julie Lisano
Close
Sort by
Journal Articles

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Gilles Salles, Alison J. Moskowitz, Armando Santoro, Amitkumar Mehta, Paul M. Barr, Neha Mehta-Shah, Graham P. Collins, Stephen M. Ansell, Joshua D. Brody, Eva Domingo-Domenech, Nathalie A. Johnson, David Cunningham, Silvia Ferrari, Julie Lisano, Jennifer Krajewski, Rachael Wen, Alev Akyol, Russell Crowe, Kerry J. Savage
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2400–2404.
https://doi.org/10.1182/bloodadvances.2023011030
Published: 2024
Includes: Supplemental data
Journal Articles

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Clinical Trials & Observations
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5272–5280.
https://doi.org/10.1182/bloodadvances.2023010254
Published: 2023
Includes: Supplemental data
Journal Articles

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

Clinical Trials & Observations
Steven M. Horwitz, Julia J. Scarisbrick, Reinhard Dummer, Sean Whittaker, Madeleine Duvic, Youn H. Kim, Pietro Quaglino, Pier Luigi Zinzani, Oliver Bechter, Herbert Eradat, Lauren Pinter-Brown, Oleg E. Akilov, Larisa Geskin, Jose A. Sanches, Pablo L. Ortiz-Romero, Michael Weichenthal, David C. Fisher, Jan Walewski, Judith Trotman, Kerry Taylor, Stephane Dalle, Rudolf Stadler, Julie Lisano, Veronica Bunn, Meredith Little, H. Miles Prince
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5098–5106.
https://doi.org/10.1182/bloodadvances.2021004710
Published: 2021
Includes: Supplemental data